Guest speaker: Dr. Christine Kay, M.D., Vitreoretinal Surgeon and Director of Clinical Research at Vitreoretinal Associates
In this webinar, Dr. Christine Kay, discusses the use of the FST as a clinical trial endpoint for severe retinal diseases. She introduced the FST as a psychophysical method for measuring luminance threshold across the entire retina. She explained how red and blue light stimuli can be used to distinguish rod and cone function. Dr. Kay emphasizes FST’s growing role in clinical research, particularly as a measure of visual function for patients with severe retinal disease, where traditional visual acuity assessments fall short.